Nanoscope Therapeutics is pioneering advancements in gene therapy aimed at restoring vision for patients suffering from inherited retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt disease. The company’s lead product, MCO-010, utilizes a proprietary approach that incorporates ambient light-sensitive molecules known as Multi-Characteristic Opsins (MCO). This innovative therapy is designed to deliver these light-sensitive proteins directly into retinal cells, enabling them to respond to ambient light and potentially restore vision in individuals with varying degrees of retinal degeneration. Nanoscope's technology is notable for its mutation-agnostic nature, meaning it can address a wide range of genetic mutations that lead to vision loss, thereby broadening its applicability across different patient populations.

In addition to MCO-010, Nanoscope has recently licensed the CatCh technology from the Max Planck Institute for Biophysics, which enhances the light sensitivity of their optogenetic therapies. This technology allows for the creation of a fusion protein that is sensitive across the visible spectrum and operates effectively under ambient light conditions. The integration of CatCh into the MCO platform is expected to improve the therapeutic outcomes for patients with severe degenerative retinal conditions. Nanoscope is actively advancing its clinical trials, having received FDA fast track and orphan drug designations for MCO-010, and is working towards making this groundbreaking treatment available to patients in need.

United States

Nanoscope is focused on proprietary ambient light activated optogenetic therapy to restore vision in people suffering from all forms of Retinitis Pigmentosa.

Nanoscope Therapeutics

Company Details